Day Zero Diagnostics

Info

Contact Jong Lee
Title CEO & Co-Founder

Description

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases.

With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

Company News

Day Zero Diagnostics Wins $300K NIH Grant to Refine HAI Outbreak Analysis Service

/
DateDec 9, 2020
Infectious disease startup Day Zero Diagnostics last week received a $300,000 grant from the National Institutes of Health to further develop its nanopore sequencing-based technology for the analysis of healthcare-associated infection (HAI) outbreaks.
Read More →

Day Zero Diagnostics wins $6.2m from accelerator

/
DateMay 12, 2020
Boston-based Day Zero said in a news release that its system helps offer the most effective antibiotic treatment on the first day that patients are admitted to the hospital, rather than having them undergo multiple days of toxic broad-spectrum antibiotics to prevent septic shock.
Read More →

Day Zero Diagnostics: New Diagnostic Rapidly Identifies The Resistance Profile of Bacteria, Enabling Targeted Therapy Sooner

/
DateJan 17, 2018
At the 2017 meeting of AdvaMed, the medical device industry’s advocacy organization, young start-up Day Zero Diagnostics was chosen as this year’s MedTech Innovator Global Competition winner.

Day Zero Diagnostics is 2017 MedTech Innovator Global Competition Winner

/
DateSep 26, 2017
MedTech Innovator announced today Day Zero Diagnostics as the winner of its 2017 global competition. The Boston-based company was selected in a real-time vote by an audience of nearly 1,500 at The MedTech Conference powered by AdvaMed.